Scott A. Mccomb

451 Smyth Rd, K1H 8M5
Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

An apples-to-apples comparison of VHH and scFv antigen-binding domains in CAR-T cells.

An apples-to-apples comparison of VHH and scFv antigen-binding domains in CAR-T cells.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 04, 2026

Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies.

Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies.

Journal: Frontiers in cell and developmental biology

Published: February 12, 2026

Introduction to the Immune System.

Introduction to the Immune System.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 14, 2025

Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease.

Anti-BCMA-CAR-IL15 natural killer cells prevent multiple myeloma growth in the bone marrow but allow subsequent emergence of extramedullary disease.

Journal: Cancer letters

Published: July 30, 2025

Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.

Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression.

Journal: Frontiers in immunology

Published: November 22, 2024

Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells.

Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells.

Journal: Antibody therapeutics

Published: November 21, 2024

Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies.

Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies.

Journal: Cytotherapy

Published: September 05, 2024

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis.

Journal: Transfusion medicine reviews

Published: May 22, 2024

A Flow Cytometry-Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells.

A Flow Cytometry-Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells.

Journal: Bio-protocol

Published: January 24, 2024

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

Journal: Nature communications

Published: October 12, 2023

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.

Journal: Molecular therapy. Oncology

Published: September 29, 2023

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.

Journal: Frontiers in immunology

Published: February 14, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026